AMENDMENTS TO THE CLAIMS

This listing of claims replaces all prior versions and listings of claims.

- 1. (Currently amended) The use of <u>a medicament containing</u> alprostadil for producing a medicament for angioneogenesis.
- 2. (Currently amended) The use as claimed in claim 1, characterized in that wherein the angioneogenesis is employed within the framework of the treatment of chronic heart failure and/or cardiomyopathy.
- 3. (Currently amended) The use as claimed in claim 1, c characterized in that wherein the angioneogenesis is employed within the framework of a neovascularization.
- 4. (Currently amended) The use as claimed in claim 1, characterized in that wherein the angioneogenesis is used to reduce the degree of fibrosis.
- 5. (Currently amended) The use as claimed in claim 1 characterized in that wherein the angioneogenesis is used for regression of hypertrophy.
- 6. (Currently amended) The use as claimed in claim 1, characterized in that wherein the angioneogenesis for revitalization of dead areas of the heart, especially after a myocardial infarction.
- 7. (Currently amended) The use as claimed in claim 1, characterized in that wherein the angioneogenesis is used for the treatment of advanced peripheral arterial occlusive diseases.
- 8. (Currently amended) The use as claimed in claim 1, characterized in that wherein the angioneogenesis is used for the treatment of diabetic angiopathy.
- 9. (Currently amended) The use as claimed in claim 1, characterized in that wherein the angioneogenesis is used for the treatment of systemic lung disorders, especially pulmonary fibrosis.

- 10. (Currently amended) The use as claimed in claim 1, characterized in that wherein the angioneogenesis is used for the treatment of acute or chronic renal failure and glomerulonephritis.
- 11. (Currently amended) The use as claimed in claim 1, characterized in that wherein the angioneogenesis is used for the treatment of acute or chronic hepatic failure.
- 12. (Currently amended) The use as claimed in claim 1, characterized in that wherein the angioneogenesis is used for the treatment of cerebral infarction.
- 13. (New) A medicament for angioneogenesis comprising alprostadil, wherein the angioneogenesis is used in a treatment selected from the group consisting of (a) treatment of chronic heart failure and/or cardiomyopathy,
- (b) treatment involving neovascularization, (c) treatment to reduce fibrosis,
- (d) treatment for regression of hypertrophy, (e) treatment to revitalize dead areas of the heart, (f) treatment of advanced peripheral arterial occlusive diseases,
- (g) treatment of diabetic angiopathy; (h) treatment of systematic lung disorders;
- (i) treatment of renal failure; (k) treatment of glomerulonephritis; (j) treatment of hepatic failure, and (l) treatment of cerebral infarction.

3